Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

By I. Janoueix-Lerosey, D. Lequin, L. Brugières, A. Ribeiro, L. Pontual, V. Combaret, V. Raynal, A. Puisieux, G. Schleiermacher, G. Pierron and 6 more. Nature, 2008

908 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Neurology

View Paper: https://www.semanticscholar.org/paper/5a4a490ba089c0c8e95f08f90809dd9c42f86a73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Dirk Walther

Citations in the corpus

• Neuroblastoma and MYCN (2013, background): “Gain of function mutations in the receptor tyrosine kinase ALK (chromosome 2p23) occur in 50% of familial neuroblastoma cases, and 7% of sporadic neuroblastoma cases (Chen et al. 2008; George et al. 2008; Janoueix-Lerosey et al. 2008; Mossé et al. 2008; Molenaaret al. 2012b).”
• The Roles of Post-translational Modifications in the Context of Protein Interaction Networks (2015, background): “ALK tyrosine kinase receptor ENSP00000373700 Neuroblastoma 3 (NBLST3) [MIM:613014] [76]”